Halozyme Therapeutics, Inc. (NASDAQ:HALO) Receives Consensus Rating of “Moderate Buy” from Analysts

Shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO) have earned a consensus rating of “Moderate Buy” from the thirteen ratings firms that are presently covering the firm, Marketbeat reports. One analyst has rated the stock with a sell recommendation, four have given a hold recommendation and eight have issued a buy recommendation on the company. The average 1 year target price among brokers that have issued ratings on the stock in the last year is $78.80.

Several equities research analysts have issued reports on the stock. Citigroup restated a “market outperform” rating on shares of Halozyme Therapeutics in a research report on Tuesday, November 4th. Zacks Research cut Halozyme Therapeutics from a “strong-buy” rating to a “hold” rating in a report on Monday, October 6th. Wall Street Zen lowered Halozyme Therapeutics from a “strong-buy” rating to a “buy” rating in a report on Saturday, December 6th. Morgan Stanley dropped their target price on Halozyme Therapeutics from $80.00 to $79.00 and set an “overweight” rating for the company in a report on Monday, October 20th. Finally, Citizens Jmp boosted their target price on shares of Halozyme Therapeutics from $91.00 to $92.00 and gave the company a “market outperform” rating in a research report on Tuesday, November 4th.

Halozyme Therapeutics Trading Down 0.6%

HALO stock opened at $71.29 on Friday. Halozyme Therapeutics has a one year low of $47.50 and a one year high of $79.50. The stock has a market cap of $8.38 billion, a price-to-earnings ratio of 15.01, a price-to-earnings-growth ratio of 0.32 and a beta of 0.94. The company has a fifty day moving average price of $68.79 and a two-hundred day moving average price of $67.75. The company has a debt-to-equity ratio of 1.59, a current ratio of 1.59 and a quick ratio of 1.37.

Halozyme Therapeutics (NASDAQ:HALO) last posted its earnings results on Monday, November 3rd. The biopharmaceutical company reported $1.72 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.63 by $0.09. The company had revenue of $354.26 million during the quarter, compared to analysts’ expectations of $339.18 million. Halozyme Therapeutics had a net margin of 47.91% and a return on equity of 156.95%. Halozyme Therapeutics’s quarterly revenue was up 22.1% compared to the same quarter last year. During the same quarter last year, the company posted $1.27 EPS. Equities analysts anticipate that Halozyme Therapeutics will post 4.73 EPS for the current year.

Insider Buying and Selling at Halozyme Therapeutics

In related news, Director Bernadette Connaughton sold 2,000 shares of the business’s stock in a transaction that occurred on Monday, January 5th. The stock was sold at an average price of $70.25, for a total value of $140,500.00. Following the completion of the sale, the director directly owned 40,123 shares in the company, valued at approximately $2,818,640.75. The trade was a 4.75% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is accessible through this link. Also, CEO Helen Torley sold 16,569 shares of the stock in a transaction that occurred on Monday, December 1st. The stock was sold at an average price of $68.92, for a total value of $1,141,935.48. Following the sale, the chief executive officer directly owned 708,719 shares in the company, valued at $48,844,913.48. This represents a 2.28% decrease in their position. The SEC filing for this sale provides additional information. Insiders sold 45,661 shares of company stock valued at $3,139,257 in the last quarter. Company insiders own 2.40% of the company’s stock.

Hedge Funds Weigh In On Halozyme Therapeutics

Several hedge funds and other institutional investors have recently added to or reduced their stakes in HALO. Azzad Asset Management Inc. ADV grew its holdings in shares of Halozyme Therapeutics by 1.6% during the 4th quarter. Azzad Asset Management Inc. ADV now owns 12,121 shares of the biopharmaceutical company’s stock worth $816,000 after purchasing an additional 191 shares in the last quarter. Sugar Maple Asset Management LLC raised its stake in Halozyme Therapeutics by 24.3% in the fourth quarter. Sugar Maple Asset Management LLC now owns 12,800 shares of the biopharmaceutical company’s stock valued at $861,000 after purchasing an additional 2,500 shares in the last quarter. Element Squared LLC acquired a new stake in Halozyme Therapeutics during the fourth quarter worth about $1,193,000. Tema Etfs LLC bought a new position in Halozyme Therapeutics in the 4th quarter valued at about $1,700,000. Finally, Allspring Global Investments Holdings LLC increased its holdings in Halozyme Therapeutics by 6.5% in the 4th quarter. Allspring Global Investments Holdings LLC now owns 29,938 shares of the biopharmaceutical company’s stock valued at $2,105,000 after buying an additional 1,821 shares during the period. 97.79% of the stock is owned by institutional investors and hedge funds.

Halozyme Therapeutics Company Profile

Halozyme Therapeutics, Inc is a biopharmaceutical company headquartered in San Diego, California, that specializes in the development and commercialization of novel drug-delivery technologies. Founded in 1998, Halozyme focuses on enabling subcutaneous administration of biologic therapies through its proprietary platforms. The company’s core mission is to improve patient access and convenience while maintaining efficacy and safety profiles comparable to or better than traditional routes of administration.

The company’s flagship technology, ENHANZE®, is based on recombinant human hyaluronidase PH20 (rHuPH20), an enzyme that transiently degrades hyaluronan in the extracellular matrix.